US 2015/0175993 A1Published application

Novel synzymes

AssigneeThe Regents of the University of California

InventorsMichael J. Heller, Tsukasa Takahashi, Michelle Lillian Cheung

Life of this patent

Estimating the term…

Abstract

Novel synthetic catalytic structures or “synzymes,” e.g., synthetic polypeptides, with catalytic properties are provided. It is believed that these synthetic catalytic structures mimic some of the precise conformational changes necessary for catalytic activities seen in enzymes. The catalytic properties of these synthetic catalytic structures or synzymes can be further improved by the application of controlled external forces, e.g., electric fields.

Claims42

Dependent claims

A synthetic polypeptide comprising the amino acid sequence X1-X2-X3-X4-X5 (SEQ ID NO:1), wherein

X1, X3, and X5 are independently selected from the group consisting of alanine, an alanine analog, phenylalanine, and a phenylalanine analog;
X2 and X4 are independently selected from the group consisting of cysteine, a cysteine analog, serine, a serine analog, histidine, and a histidine analog;
wherein when X2 is histidine or a histidine analog, X4 is cysteine or a cysteine analog, or serine or a serine analog;
wherein when X4 is histidine or histidine analog, X2 is cysteine or cysteine analog, or serine or serine analog;
wherein the synthetic polypeptide is from 6 to 30 amino acids total in length;
wherein the alanine analog is selected from the group consisting of β-alanine, dehydroalanine, aminoisobutyric acid, valine and norvaline;
wherein the phenylalanine analog is selected from the group consisting of methylphenylalanine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, phenylglycine, ethyltyrosine, and methyltyrosine;
wherein the cysteine analog is selected from the group consisting of homocysteine and penicillamine;
wherein the serine analog is selected from the group consisting of methylserine, threonine, 2-amino-3-hydroxy-4-methylpentanoic acid, 3-amino-2-hydroxy-5-methylhexanoic acid, 4-amino-3-hydroxy-6-methylheptanoic acid, and 2-amino-3-hydroxy-3-methylbutanoic acid;
wherein the histidine analog is selected from the group consisting of β-(1,2,3-triazol-4-yl)-DL-alanine, and 1,2,4-triazole-3-alanine.

7 more elements

A synthetic polypeptide comprising an amino acid sequence selected from the group consisting of:

Ala-Cys-Ala-His-Ala (SEQ ID NO:
2);
Ala-Ser-Ala-His-Ala (SEQ ID NO:
3);
Phe-Cys-Phe-His-Ala (SEQ ID NO:
4);
Phe-Ser-Phe-His-Ala (SEQ ID NO:
5);
Phe-His-Phe-Cys-Ala (SEQ ID NO:
6);
Phe-His-Phe-Ser-Ala (SEQ ID NO:
7);
Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO:
8);
Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO:
9);
Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO:
10);
Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO:
11);
Asp-Phe-His-Phe-Cys-Ala (SEQ ID NO:
12);
Asp-Phe-His-Phe-Ser-Ala (SEQ ID NO:
13);
Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO:
14);
Ala-Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO:
15);
Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO:
16);
Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO:
17);
Asp-Phe-His-Phe-Cys-Ala-Gly (SEQ ID NO:
18);
Asp-Phe-His-Phe-Ser-Ala-Gly (SEQ ID NO:
19);
Gly-Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO:
20);
Gly-Ala-Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO:
21);
Gly-Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO:
22);
Gly-Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO:
23);
Asp-Phe-His-Phe-Cys-Ala-Gly-Asp (SEQ ID NO:
24);
Asp-Phe-His-Phe-Ser-Ala-Gly-Asp (SEQ ID NO:
25);
Gly-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO:
26);
Arg-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp (SEQ ID NO:
27);
Arg-Gly-Ala-Ala-Ser-Ala-His-Ala-Asp (SEQ ID NO:
28);
Arg-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO:
29);
Lys-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp (SEQ ID NO:
30);
Arg-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO:
31);
Lys-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp (SEQ ID NO:
32);
Arg-Asp-Phe-His-Phe-Cys-Ala-Gly-Asp (SEQ ID NO:
33);
Arg-Asp-Phe-His-Phe-Ser-Ala-Gly-Asp (SEQ ID NO:
34);
Arg-Gly-His-Gly-Gly-Pro-Gly-Gly-His-Gly-Cys-Gly-Asp (SEQ ID NO:
36);
and
Arg-Gly-Gly-His-Phe-Cys-Gly-Pro-Gly-His-Gly-His-Gly-Asp (SEQ ID NO:
37), and
wherein the synthetic polypeptide is from 6 to 30 amino acids total in length.

69 more elements

An array of synthetic polypeptides comprising at least two synthetic polypeptides, wherein each synthetic polypeptide is from 9 to 15 amino acids total in length and comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO:
2)
Ala-Cys-Ala-His-Ala;
(SEQ ID NO:
3)
Ala-Ser-Ala-His-Ala;
(SEQ ID NO:
4)
Phe-Cys-Phe-His-Ala;
(SEQ ID NO:
5)
Phe-Ser-Phe-His-Ala;
(SEQ ID NO:
6)
Phe-His-Phe-Cys-Ala;
(SEQ ID NO:
7)
Phe-His-Phe-Ser-Ala;
(SEQ ID NO:
8)
Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO:
9)
Ala-Ser-Ala-His-Ala-Asp;
(SEQ ID NO:
10)
Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO:
11)
Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO:
12)
Asp-Phe-His-Phe-Cys-Ala;
(SEQ ID NO:
13)
Asp-Phe-His-Phe-Ser-Ala;
(SEQ ID NO:
14)
Ala-Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO:
15)
Ala-Ala-Ser-Ala-His-Ala-Asp;
(SEQ ID NO:
16)
Ala-Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO:
17)
Ala-Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO:
18)
Asp-Phe-His-Phe-Cys-Ala-Gly;
(SEQ ID NO:
19)
Asp-Phe-His-Phe-Ser-Ala-Gly;
(SEQ ID NO:
20)
Gly-Ala-Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO:
21)
Gly-Ala-Ala-Ser-Ala-His-Ala-Asp;
(SEQ ID NO:
22)
Gly-Ala-Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO:
23)
Gly-Ala-Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO:
24)
Asp-Phe-His-Phe-Cys-Ala-Gly-Asp;
(SEQ ID NO:
25)
Asp-Phe-His-Phe-Ser-Ala-Gly-Asp;
(SEQ ID NO:
26)
Gly-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO:
27)
Arg-Gly-Ala-Ala-Cys-Ala-His-Ala-Asp;
(SEQ ID NO:
28)
Arg-Gly-Ala-Ala-Ser-Ala-His-Ala-Asp;
(SEQ ID NO:
29)
Arg-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO:
30)
Lys-Gly-Ala-Phe-Cys-Phe-His-Ala-Asp;
(SEQ ID NO:
31)
Arg-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO:
32)
Lys-Gly-Ala-Phe-Ser-Phe-His-Ala-Asp;
(SEQ ID NO:
33)
Arg-Asp-Phe-His-Phe-Cys-Ala-Gly-Asp;
(SEQ ID NO:
34)
Arg-Asp-Phe-His-Phe-Ser-Ala-Gly-Asp;
(SEQ ID NO:
36)
Arg-Gly-His-Gly-Gly-Pro-Gly-Gly-His-
Gly-Cys-Gly-Asp;
and
(SEQ ID NO:
37)
Arg-Gly-Gly-His-Phe-Cys-Gly-Pro-Gly-
His-Gly-His-Gly-Asp.

105 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/406,999Filed 20 Jun 2013
Priority: 20 Jun 2012
Published: 25 Jun 2015
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

C12N 9/50
Acting on peptide bonds: proteinases , e.g. Endopeptidases
C12N 13/00
Treatment of microorganisms or enzymes with electrical or wave energy
C07K 7/06
Linear peptides containing only normal peptide links: having 5 to 11 amino acids
C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids

Family

Application61/662,302Us provisional application · filed 20 Jun 2012
US 9,976,133 B2Related patent
US 2015/0175993 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

Facts

Application

14/406,999Filed 20 Jun 2013

Priority

20 Jun 2012

Published

25 Jun 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

C12N 9/50
Acting on peptide bonds: proteinases , e.g. Endopeptidases
C12N 13/00
Treatment of microorganisms or enzymes with electrical or wave energy
C07K 7/06
Linear peptides containing only normal peptide links: having 5 to 11 amino acids
C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids